Comparing Genmab A/S (GMAB) & Its Competitors

Genmab A/S (NASDAQ:GMAB) is one of 847 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Genmab A/S to similar businesses based on the strength of its profitability, institutional ownership, valuation, dividends, analyst recommendations, risk and earnings.

Volatility and Risk

Genmab A/S has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Genmab A/S’s competitors have a beta of 1.07, meaning that their average stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Genmab A/S and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Genmab A/S Competitors	-9,046.42%	-198.98%	-30.68%

Insider and Institutional Ownership

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Genmab A/S and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Genmab A/S	$4.13 billion	$963.00 million	45.11
Genmab A/S Competitors	$695.88 million	$9.64 million	-10.01

Genmab A/S has higher revenue and earnings than its competitors. Genmab A/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Genmab A/S and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0	3	9	1	2.85
Genmab A/S Competitors	9766	15000	45311	1578	2.54

Genmab A/S presently has a consensus target price of $44.39, suggesting a potential downside of 22.52%. As a group, “Biotechnology” companies have a potential upside of 90.96%. Given Genmab A/S’s competitors higher probable upside, analysts clearly believe Genmab A/S has less favorable growth aspects than its competitors.

Summary

Genmab A/S beats its competitors on 9 of the 13 factors compared.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.